Acute Lymphoblastic Leukemia | CHOP Research Institute
 

Acute Lymphoblastic Leukemia

22CT015: CART 19-22 co-administration

This is a Phase 1/2b trial for the treatment of patients with either advanced or refractory B cell Acute Lymphoblastic Leukemia or B-lineage lymphoblastic lymphoma.

Global CTL019

The purpose of this study is to evaluate the efficacy of Cart 19 cells therapy as measured by overall remission rate, which includes Complete Remission and Complete Remission with incomplete blood count recovery assessment in infants to adults.

Stephan Kadauke, MD, PhD
Stephan Kadauke

Dr. Kadauke is the associate director of the Cell and Gene Therapy Laboratory at CHOP and the medical director of the Cell and Gene Therapy Informatics team. His research focuses on developing novel ways to manufacture cell therapies with the goal of accelerating and broadening patient access to these life-saving therapies.

E-mail:
kadaukes [at] chop.edu

Prodigy huCART19

This study will determine the safety and usefulness of using the CliniMACS Prodigy platform to manufacture huCART19 cells.

UCART22

UCART22

The purpose of this study is to determine the safety and tolerability of an experimental form of therapy, known as UCART22 ("study drug").

Where Discovery Leads: Taking CAR T-Cell Therapy to Solid Tumors and Beyond

Published on
Sep 19, 2022
in Cornerstone Blog
Where Discovery Leads: CAR T-Cell Therapy Research
CHOP physician-scientists discuss their CAR T-cell therapy research for childhood cancers in Where Discovery Leads.

In the News: Mitochondrial Disease, ALL, Type 2 Diabetes, Sleep Apnea

Published on
Sep 16, 2022
in Cornerstone Blog
In the News
This week’s In the News highlights research on mitochondrial disease, acute lymphoblastic leukemia, type 2 diabetes, and sleep apnea.

TACL-2020-003; IDEAL2 Study

The purposes of this study is to examine efficacy of the IDEAL2 (Improving Diet and Exercise in ALL) caloric restriction and activity intervention integrated into HR B-ALL induction to reduce incidence of end of induction (EOI) MRD ≥0.01%.

Allo CD7 CAR WU-CART-007

The purpose of this study is to determine the safety and tolerability of an experimental form of therapy, known as WU-CART-007 (“study drug”). 

Looking to Enhance Lifelong Health in Young HCT Survivors by Focusing on Muscle

Published on
Jun 8, 2022
in Cornerstone Blog
Focusing on Muscle in Young Bone Marrow Transplant Survivors
CHOP docs are leading IAMFIT, a clinical study testing an exercise intervention to enhance lifelong health for young HCT survivors.